A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
This study is to evaluate the efficacy and safety of AK104 plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer
Locally Advanced Cervical Carcinoma
DRUG: AK104|RADIATION: EBRT|RADIATION: BT|DRUG: cisplatin|DRUG: Placebo
Progression-Free Survival(PFS) by investigator(INV), PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1 and/or biopsy, 54 months
PFS rate at month 36, PFS rate at month 36, 36 months|Overall Survival(OS), OS is defined as the time from randomization to death due to any cause., 5 years
This study is to evaluate the efficacy and safety of AK104 plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer